Skip to main content

Diatrizoate Pregnancy and Breastfeeding Warnings

Brand names: Angiografin, Cardiografin, Cystografin, Cystografin-Dilute, Gastrografin, Hypaque, Hypaque Cysto, Hypaque Meglumine, Hypaque Sodium, Hypaque-76, Hypaque-M, MD-76, MD-Gastroview, Reno-30, Reno-60, Reno-Dip, Reno-M-30, Reno-M-60, Reno-M-DIP, Renocal-76, Renografin-60, Renografin-76, Renovist, Renovist II, Urovison

Diatrizoate Pregnancy Warnings

AU: Use is contraindicated.
UK, US: Use is not recommended unless clearly needed.

AU TGA pregnancy category: Not assigned
US FDA pregnancy category: C

Animal reproduction studies have not been conducted with diatrizoate meglumine injection. It is also not known whether diatrizoate meglumine injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Adequate and well-controlled studies in pregnant women have not been conducted

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Diatrizoate Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Yes

Comments: The effects in the nursing infant are unknown.

See references

See also

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer